Everyone’s Health Needs a Great Sidekick…Sidekick Health is Here!

 

To bolster patient-centric treatment, what healthcare could use is a great sidekick.

The healthcare landscape is at a critical juncture, with chronic diseases escalating and healthcare systems worldwide struggling under the weight of increasing demands and costs. It’s a pressing issue, considering poor medication adherence contributes to an estimated 125,000 deaths each year across the U.S. With chronic diseases on the rise and healthcare costs ballooning, how can digital innovation forge the path toward more proactive, patient-centered healthcare?

In this episode of “Healthcare Rethink,” host Brian Urban welcomes Dr. Tryggvi Thorgeirsson, MD, MPH, the CEO of Sidekick Health. They explore Sidekick Health’s mission to transition healthcare from a reactive to a proactive service and how it’s making patient empowerment a reality.

Key points of discussion:

  • Sidekick Health’s genesis and its global impact on chronic disease management
  • The company’s adaptive care path model and its success in improving clinical outcomes
  • The integration of behavioral sciences to enhance patient engagement and adherence

Dr. Tryggvi Thorgeirsson is a practicing physician and an innovator in public health. With an MPH from Harvard and a role as an adviser to the Icelandic prime minister, Dr. Thorgeirsson represents a fusion of clinical expertise and a commitment to technology-driven healthcare solutions.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…